Brightsurf Science News & Current Events

December 09, 2006
Eculizumab is well-tolerated and shows significant improvement in PNH patients (Ph III)
Eculizumab, a MAb drug, appeared safe and well-tolerated, and provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH) in a Phase 3 open-label, 52 weeks of treatment trial. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to